ReviewVirology journal2025
Antiviral treatment for viral pneumonia: current drugs and natural compounds.
Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Therapeutic effects of traditional Chinese medicine injections with heat-clearing and detoxifying properties on viral pneumonia: a systematic review and network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of nebulized inhalation vs. intramuscular delivery of interferon α1b injection for paediatric patients with viral respiratory diseases: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis.Frontiers in microbiology · 2025Pooled it
- Folate-mediated inflammatory microenvironment-responsive nanocarriers for the delivery of Moringa A to target NLRP3 for the treatment of viral pneumonia.International journal of pharmaceutics: X · 2026Article
- Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026Review
- Impact of pathogen co-detection on disease severity and clinical outcomes in children with Mycoplasma pneumoniae pneumonia.World journal of pediatrics : WJP · 2026Article
- Chemical Compositions, Traditional Applications, and Biological Activities ofMolecules (Basel, Switzerland) · 2026Review
- Multi-omics analysis of host airway responses in pediatric Mycoplasma pneumoniae pneumonia reveals potential mechanisms of disease exacerbation caused by co-infection.NPJ biofilms and microbiomes · 2025Article
- Biodiversity to Breakthroughs: The Promise of Saudi Arabian Medicinal Plants in Antiviral Research.Applied biochemistry and biotechnology · 2025Review
- Geographical Variation Shapes Nutritional Metabolite Profile and Food Functionality ofMetabolites · 2025Article
- Natural products alleviate viral pneumonia by modulating inflammatory and oxidative-stress pathways.Frontiers in pharmacology · 2025Review
- Targeting ZBP1-Mediated PANoptosis: Inflammation-Responsive Selenized Chitosan Nanoparticles Loaded with Moringa A for Antiviral Pneumonia Therapy.Biomaterials research · 2025Article
- Xuebijing injection in the treatment of COVID-19: An update on clinical studies, potentially active metabolites and mechanisms.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In recent years, viral pneumonia has become a significant challenge to global public health, particularly during the COVID-19 pandemic. Viral pneumonia can be caused by various viruses, including influenza virus, RSV, and adenovirus. These viruses trigger inflammatory responses by invading the respiratory epithelial cells, leading to lung damage. Existing antiviral drugs such as ribavirin, adobiravir, and oseltamivir exert their therapeutic effects by inhibiting different stages of the viral life cycle but face issues such as increasing drug resistance. Natural components like astragalus saponins, Houttuynia cordata flavonoids, and tea theaflavin-gallates have demonstrated supportive roles in antiviral treatments, capable of not only enhancing immune responses but also potentially inhibiting viral replication through multiple pathways, thereby alleviating lung damage. Although natural components cannot entirely replace traditional antiviral drugs, their role in comprehensive treatment regimens is becoming increasingly important. This review summarizes the current applications and limitations of antiviral drugs and explores the research progress and potential mechanisms of natural components in the treatment of viral pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.